Orion Entered into a Research Collaboration with Peptilogics to Enable AI-Driven Drug Discovery Against Undrugged GPCR Target
Shots:
- The collaboration will combine Peptilogics’ Nautilus AI-driven peptide design platform with Orion’s GPCR platform for drug discovery against an undrugged peptidergic GPCR to treat prevalent, life-threatening diseases
- Peptilogics use its Nautilus platform to create multiparameter-optimized peptides with the ability to target both novel and historically difficult therapeutic targets by combining deep generative algorithms, predictive models, and biophysical simulation
- Orion’s platform explores the receptor-ligand shape space to produce precision-engineered peptides with increased potency and specialized signaling activity by utilizing patented multiplex synthesis technology
Ref: GlobalNewswire | Image: Orion
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
